Role of NF-κB in Platelet Function

Int J Mol Sci. 2019 Aug 27;20(17):4185. doi: 10.3390/ijms20174185.

Abstract

Platelets are megakaryocyte-derived fragments lacking nuclei and prepped to maintain primary hemostasis by initiating blood clots on injured vascular endothelia. Pathologically, platelets undergo the same physiological processes of activation, secretion, and aggregation yet with such pronouncedness that they orchestrate and make headway the progression of atherothrombotic diseases not only through clot formation but also via forcing a pro-inflammatory state. Indeed, nuclear factor-κB (NF-κB) is largely implicated in atherosclerosis and its pathological complication in atherothrombotic diseases due to its transcriptional role in maintaining pro-survival and pro-inflammatory states in vascular and blood cells. On the other hand, we know little on the functions of platelet NF-κB, which seems to function in other non-genomic ways to modulate atherothrombosis. Therein, this review will resemble a rich portfolio for NF-κB in platelets, specifically showing its implications at the levels of platelet survival and function. We will also share the knowledge thus far on the effects of active ingredients on NF-κB in general, as an extrapolative method to highlight the potential therapeutic targeting of NF-κB in coronary diseases. Finally, we will unzip a new horizon on a possible extra-platelet role of platelet NF-κB, which will better expand our knowledge on the etiology and pathophysiology of atherothrombosis.

Keywords: NF-κB; inflammation; platelet; signaling pathways; thrombosis.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Blood Platelets / drug effects
  • Blood Platelets / metabolism*
  • Blood Platelets / physiology
  • Humans
  • NF-kappa B / genetics
  • NF-kappa B / metabolism*
  • Platelet Activation
  • Platelet Aggregation Inhibitors / pharmacology

Substances

  • Anti-Inflammatory Agents
  • NF-kappa B
  • Platelet Aggregation Inhibitors